FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300687316> ?p ?o ?g. }

• W4300687316 endingPage "10" @default.
• W4300687316 startingPage "1" @default.
• W4300687316 abstract "To present real-life data of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) treated with bevacizumab (BVZ); determine the possible influence of epiretinal membrane (ERM) on treatment efficacy; and compare treatment outcomes in a treat-and-extend regimen (TER) versus pro re nata (PRN).We carried out a retrospective analysis of 58 eyes (56 patients) with new-onset CRVO treated only with intravitreal bevacizumab according to TER or PRN. Outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and 12 months after the first treatment, number of visits and injections, and presence of ERM confirmed by optical coherence tomography in the first 6 months.At 12 months, the mean number of injections was 6.3 across all eyes, with significantly more injections given in TER (p < 0.001). Mean CRT improved from 627 μm to 359 μm (p < 0.001) in all eyes, with improvement noted in TER (p < 0.001), PRN (p < 0.001), ERM (p=0.003), and non-ERM (p < 0.001) subgroups. The mean BCVA gain was +13.6 letters, and the mean BCVA improved from 0.81 to 0.54 LogMAR (p < 0.001) in all eyes. BCVA improvement from baseline was significant in TER (p < 0.001) and non-ERM (p < 0.001) but not in PRN (p=0.08) or ERM (p=0.2) subgroups. Seven eyes, all receiving PRN treatment, developed neovascularization.Intravitreal bevacizumab according to either PRN or TER resolved edema and stabilized vision in the first 12 months, with TER yielding significant visual improvement and avoiding neovascular complications. ERM had no influence on bevacizumab efficacy in reducing ME in CRVO during 12 months of treatment." @default.
• W4300687316 created "2022-10-04" @default.
• W4300687316 creator A5011266026 @default.
• W4300687316 creator A5022620904 @default.
• W4300687316 creator A5041825330 @default.
• W4300687316 creator A5050807282 @default.
• W4300687316 creator A5063985558 @default.
• W4300687316 creator A5072784630 @default.
• W4300687316 date "2022-10-03" @default.
• W4300687316 modified "2023-10-01" @default.
• W4300687316 title "Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane" @default.
• W4300687316 cites W1250069669 @default.
• W4300687316 cites W1594638966 @default.
• W4300687316 cites W1774049372 @default.
• W4300687316 cites W1898187276 @default.
• W4300687316 cites W1971399814 @default.
• W4300687316 cites W1972105764 @default.
• W4300687316 cites W1976154023 @default.
• W4300687316 cites W1985498685 @default.
• W4300687316 cites W1987590493 @default.
• W4300687316 cites W1995461736 @default.
• W4300687316 cites W2005764925 @default.
• W4300687316 cites W2009010044 @default.
• W4300687316 cites W2009329330 @default.
• W4300687316 cites W2014434030 @default.
• W4300687316 cites W2019605256 @default.
• W4300687316 cites W2020482183 @default.
• W4300687316 cites W2021149044 @default.
• W4300687316 cites W2031246040 @default.
• W4300687316 cites W2031329755 @default.
• W4300687316 cites W2042100597 @default.
• W4300687316 cites W2043605463 @default.
• W4300687316 cites W2046232272 @default.
• W4300687316 cites W2047858191 @default.
• W4300687316 cites W2050164779 @default.
• W4300687316 cites W2052204551 @default.
• W4300687316 cites W2056535025 @default.
• W4300687316 cites W2068659418 @default.
• W4300687316 cites W2071661100 @default.
• W4300687316 cites W2075780935 @default.
• W4300687316 cites W2078040311 @default.
• W4300687316 cites W2078485214 @default.
• W4300687316 cites W2080689845 @default.
• W4300687316 cites W2085947188 @default.
• W4300687316 cites W2088939298 @default.
• W4300687316 cites W2115060781 @default.
• W4300687316 cites W2126501086 @default.
• W4300687316 cites W2129001397 @default.
• W4300687316 cites W2146472373 @default.
• W4300687316 cites W2152718741 @default.
• W4300687316 cites W2168542493 @default.
• W4300687316 cites W2171962482 @default.
• W4300687316 cites W2172223254 @default.
• W4300687316 cites W2263979229 @default.
• W4300687316 cites W2285674438 @default.
• W4300687316 cites W2321550082 @default.
• W4300687316 cites W2346773409 @default.
• W4300687316 cites W2416911783 @default.
• W4300687316 cites W2556545510 @default.
• W4300687316 cites W2561498458 @default.
• W4300687316 cites W2608488415 @default.
• W4300687316 cites W2611530060 @default.
• W4300687316 cites W2612836720 @default.
• W4300687316 cites W2726377704 @default.
• W4300687316 cites W2739886523 @default.
• W4300687316 cites W2783439068 @default.
• W4300687316 cites W2791521942 @default.
• W4300687316 cites W2897984215 @default.
• W4300687316 cites W2901929903 @default.
• W4300687316 cites W2912199742 @default.
• W4300687316 cites W2940118684 @default.
• W4300687316 cites W3012273996 @default.
• W4300687316 cites W4235001346 @default.
• W4300687316 cites W4246878943 @default.
• W4300687316 cites W4250416245 @default.
• W4300687316 cites W4317927786 @default.
• W4300687316 cites W57049242 @default.
• W4300687316 doi "https://doi.org/10.1155/2022/6288582" @default.
• W4300687316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36225608" @default.
• W4300687316 hasPublicationYear "2022" @default.
• W4300687316 type Work @default.
• W4300687316 citedByCount "0" @default.
• W4300687316 crossrefType "journal-article" @default.
• W4300687316 hasAuthorship W4300687316A5011266026 @default.
• W4300687316 hasAuthorship W4300687316A5022620904 @default.
• W4300687316 hasAuthorship W4300687316A5041825330 @default.
• W4300687316 hasAuthorship W4300687316A5050807282 @default.
• W4300687316 hasAuthorship W4300687316A5063985558 @default.
• W4300687316 hasAuthorship W4300687316A5072784630 @default.
• W4300687316 hasBestOaLocation W43006873161 @default.
• W4300687316 hasConcept C118487528 @default.
• W4300687316 hasConcept C141071460 @default.
• W4300687316 hasConcept C2776694085 @default.
• W4300687316 hasConcept C2777802072 @default.
• W4300687316 hasConcept C2778257484 @default.
• W4300687316 hasConcept C2778844676 @default.
• W4300687316 hasConcept C2780347916 @default.
• W4300687316 hasConcept C2780699112 @default.

• next